Randomized trial demonstrates substantial and sustained body weight reduction with weekly tirzepatide in obesity, indicating an effective long-term therapy.
In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
No takes yet. Share an insight, caveat, or question.
Jastreboff et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: